MIRXES-B (02629) has announced that on April 27, 2026, the company received a letter from the Stock Exchange outlining the following guidance for the resumption of trading in its shares:
(i) Conduct an appropriate independent forensic investigation into advance payments, significant cash outflows occurring after December 31, 2025, and any other payments of a similar nature or that raise similar concerns; assess the impact on the company's business operations and financial position; announce the investigation findings; and implement appropriate remedial actions.
(ii) Demonstrate that there are no reasonable regulatory concerns regarding the integrity, competence, and/or character of the Group's management and/or any individuals with significant influence over the company's management and operations, such that they might pose risks to investors or damage market confidence.
(iii) Appoint an independent internal control advisor to conduct an independent internal control review, and demonstrate that: (i) the material weaknesses identified leading to the trading suspension have been rectified, and all necessary corrective measures have been implemented; and (ii) the company's internal controls are adequate and effective for their purpose, enabling the company to comply with the Listing Rules in all material respects, including but not limited to financial reporting, disclosure and compliance for discloseable and connected transactions, and the disclosure of material information.
(iv) Publish all outstanding financial results as required by the Listing Rules and address any audit modifications.
(v) Demonstrate that the company has complied with the provisions of Listing Rule 13.24.
(vi) Disclose all material information to the market to enable shareholders and investors to assess the company's status.
Trading in the company's shares remains suspended.
Comments